| 2 | Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma: single institution experience显示文摘Objective: The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conven- tional second-line chemotherapy. Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemo- therapy may improve both disease free survival (DFS) and overall survival (OS) of naive patients, but its role in the second-line therapy for relapsed non-Hodgkin’s Lymphoma (NHL) remains to be defined. This study aimed to evaluate the efficacy of rituximab-containing salvage regimens for relapsed or refractory NHL, and observe the toxicities. Methods: The clinical data of 54 patients, who were with relapsed or refractory NHL and treated in the Cancer Center of Sun Yat-sen University, were analyzed retrospectively. Of the 54 patients, 29 were man, 25 were women, with a median age of 52.5 years old (range 18 to 75); 50 patients (92.6%) scored 0–1 for the ECOG performance status; for second-line international prognostic index (sIPI), 21 (38.9%) scored 0–1, 30 (55.6%) scored 2 to 3, and 3 (5.6%) scored 4–5; 40 cases were diffuse large B-cell lymphoma (DLBCL), accounting for 74.1% of all subtypes. Rituximab was administered intravenously at a dose of 375 mg/m2 at the day before each chemotherapy cycle. The second or third-line salvage regimens included EPOCH, CHOP, DHAP, DICE, IVAC, IMVP-16 and FND. Results: Of the 54 patients, 49 received retuximab-containing salvage regimens. The objective response rate of the 45 evaluable cases was 68.8%, with a complete remission (CR) rate of 37.7%; 3 patients achieved CR after radiotherapy follow- ing rituximab-based regimens and 3 achieved CR after autologous hematopoietic stem cell transplantation. The most frequent adverse events were leucopenia, nausea and alopecia. The addition of rituximab to chemotherapy only elevated the occurrence of mild infusion-related reactions, such as chills, fever and pruritus. The median follow-up time was 18 months (range 2–86 months); 5 patients were lost, 24 were dead (23 died of lymphoma, and 1 died of severe hepatitis), the other patients remained alive. The median survival time was 32 months (range 2–86 months, 95% confidential interval 16–48 months). The 1-, 2- and 3-year OS rates were 70.6%, 53.6% and 41.5%, respectively. The median TTP was 6 months (range 0–52 months). The median PFS was 10 months (range 0–47 months, 95% CI 0–26 months). The 1- and 2-year PFS were 49.3% and 41.3%. Conclusion: Rituximab-containing salvage regimens are effective and well tolerated therapy for patients with relapsed or refractory B-cell NHL, even those were extensively treated. | Bufei Wang Huiqiang Huang Qjng Bu Zhongjun Xia Xubin Lin Fenghua Wang Yuhong Li Yulong Peng Zhanhe Pan Shusen Wang Tongyu Lin Wenqi Jiang Zhongzhen Guan | 2006 | The Chinese-German Journal of Clinical Oncology2006，5，6： | 1 |
| 3 | A Survey of Output Feedback Robust MPC for Linear Parameter Varying Systems显示文摘For constrained linear parameter varying(LPV)systems,this survey comprehensively reviews the literatures on output feedback robust model predictive control(OFRMPC)over the past two decades from the aspects on motivations,main contributions,and the related techniques.According to the types of state observer systems and scheduling parameters of LPV systems,different kinds of OFRMPC approaches are summarized and compared.The extensions of OFRMPC for LPV systems to other related uncertain systems are also investigated.The methods of dealing with system uncertainties and constraints in different kinds of OFRMPC optimizations are given.Key issues on OFRMPC optimizations for LPV systems are discussed.Furthermore,the future research directions on OFRMPC for LPV systems are suggested. | Xubin Ping Jianchen Hu Tingyu Lin Baocang Ding Peng Wang Zhiwu Li | 2022 | IEEE/CAA Journal of Automatica Sinica2022，9，10： | 0 |
| 4 | Advanced biosensing technologies for monitoring of agriculture pests and diseases:A review显示文摘The threat posed to crop production by pests and diseases is one of the key factors that could reduce global food security.Early detection is of critical importance to make accurate predictions,optimize control strategies and prevent crop losses.Recent technological advancements highlight the opportunity to revolutionize monitoring of pests and diseases.Biosensing methodologies offer potential solutions for real-time and automated monitoring,which allow advancements in early and accurate detection and thus support sustainable crop protection.Herein,advanced biosensing technologies for pests and diseases monitoring,including image-based technologies,electronic noses,and wearable sensing methods are presented.Besides,challenges and future perspectives for widespread adoption of these technologies are discussed.Moreover,we believe it is necessary to integrate technologies through interdisciplinary cooperation for further exploration,which may provide unlimited possibilities for innovations and applications of agriculture monitoring. | Jiayao He Ke Chen Xubin Pan Junfeng Zhai Xiangmei Lin | 2023 | Journal of Semiconductors2023，44，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员